“…Commercial antibodies used in this study were specific for Smad2/3 (rabbit polyclonal antibody, 1:1000; Cell Signaling Technology), Egr-1 (clone 44D5 rabbit monoclonal antibody [mAb], 1:1000; Cell Signaling Technology; or C-19 rabbit polyclonal antibody, 1:200; Santa Cruz Biotechnology, Santa Cruz, CA), Smad7 (goat polyclonal antibody, 1:250; Abcam, Cambridge, MA), phosphorylated Smad2 (Ser 465/467-specific, rabbit polyclonal antibody, 1:1000; Cell Signaling Technology), SM␣A (EPOS anti-human smooth muscle ␣-actin/ HRP, clone 1A4, 1:200; Dako North America, Carpiteria, CA), Erk1/2 (anti-MAP kinase p44/p42, rabbit polyclonal antibody, 1:1000; Cell Signaling Technology), phosphorylated Erk1/2 (anti-MAP kinase phospho-p44/p42, T202/ Y204-specific, clone E10 mouse mAb, 1:1000; Cell Signaling Technology), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (anti-GAPDH/HRP, 1:200; Santa Cruz Biotechnology). Rabbit polyclonal antibodies specific for YB-1 (anti-YB1 M85-110 and anti-YB1 M276-302, 1:2000) were described in our previous reports (Kelm et al, 1999). The two Egr-1-specific antibodies gave slightly different results on immunoblots owing to Egr-1 size variation, possibly because of protein phosphorylation.…”